ALLMedicine™ Renal Cell Carcinoma Center

May 20th, 2022 - Routine molecular tumour diagnostics are augmented by DNA-based qualitative and quantitative molecular techniques detecting mutations of DNA. However, in the past decade, it has been unravelled that the phenotype of cancer, as it's an extremely co...

May 19th, 2022 - We describe the case of a 75-years-old woman with history of left renal cell carcinoma that presented multiple organ dysfunction due to IVCT diagnosed by point-of-care ultrasound (POCUS) in the intensive care unit (ICU).

May 19th, 2022 - Treatment paradigms for management of metastatic renal cell carcinoma (mRCC) are evolving. We examined impact of surgical metastasectomy on survival across in mRCC stratified by risk-group. Multicenter retrospective analysis from the Registry of M...

May 18th, 2022 - In clear cell renal cell carcinoma (ccRCC), glycolysis is enhanced mainly because of the increased expression of key enzymes in glycolysis. Hence, the discovery of new molecular biomarkers for glycolysis may help guide and establish a precise syst...

May 18th, 2022 - A man in his 70s was referred to plastic surgery with a suspected foreign body in the pulp of his right index finger. An excisional biopsy was performed for a presumed foreign body granuloma. Histology revealed metastatic renal cell carcinoma (mRC...

May 14th, 2022 - Renal cell carcinoma (RCC) accounts for most malignant renal tumors and is considered the most lethal of all urologic cancers. For follow-up of patients with treated or untreated RCC and those with neoplasms suspected to represent RCC, radiologic ...

Jan 7th, 2022 - The NCCN Guidelines for Kidney Cancer focus on the screening, diagnosis, staging, treatment, and management of renal cell carcinoma (RCC). Patients with relapsed or stage IV RCC typically undergo surgery and/or receive systemic therapy. Tumor hist...

Oct 13th, 2021 - Advance diagnostic and treatment modalities have improved outcomes for renal cell carcinoma (RCC) patients, but the prognosis for those with metastatic disease (mRCC) remains poor. As given metastatic distribution is critical in guiding treatment ...

Oct 12th, 2021 - Despite guidelines recommending genetic counseling for patients with early-onset renal cell carcinoma (RCC), studies interrogating the spectrum of germline mutations and clinical associations in patients with early-onset RCC are lacking.

Oct 2nd, 2021 - ESMO Clinical Practice Guideline update on the use of immunotherapy in early stage and advanced renal cell carcinoma.|2021|Powles T,Albiges L,Bex A,Grünwald V,Porta C,|drug therapy,drug therapy,

May 13th, 2022 - Background: Rare histological variants of the GU tract include bladder/urachal adenocarcinoma, squamous cell carcinoma, and small cell carcinoma; variants of urothelial carcinoma including plasmacytoid, sarcomatoid; renal tumors including sarcomat...

May 13th, 2022 - Background: Hereditary Leiomyomatosis and Renal Cell Cancer (HLRCC) is a rare autosomal dominantly inherited disorder which confers susceptibility to develop cutaneous and uterine leiomyomas and renal cell carcinoma. HLRCC is caused by mutations i...

May 12th, 2022 - The purpose of this study is to measure how active BMS-936558 (nivolumab) is against Renal Cell Carcinoma (RCC) as measured by the disease not progressing and whether a dose response relationship exists.

May 11th, 2022 - The purpose of this study is to assess the safety and efficacy of monotherapy pembrolizumab (MK-3475) in participants with renal cell carcinoma (RCC). There will be two cohorts in this study: Cohort A will consist of participants with clear cell (...

May 11th, 2022 - Patients with localized and non-metastatic Renal Cell Carcinoma (RCC) represent an "at-need" population who would benefit from immunotherapy earlier in their disease course with a programmed cell death protein 1(PD-1) therapy combined with a secon...

May 6th, 2022 - China-based Hutchmed announced receipt of a complete response letter from the FDA, stating that the agency cannot approve the tyrosine kinase inhibitor surufatinib for advanced neuroendocrine tumors without support from a multiregional clinical tr...

May 4th, 2022 - Tian Zhang, MD: Dr Barata, can you provide a brief overview of some ongoing neoadjuvant therapy trials? In particular, we saw some data from one of the first IO [immunotherapy]/VEGF combination trials to report out, avelumab and axitinib, at ASCO ...

May 2nd, 2022 - Transcript: Robert J. Motzer, MD: Two last quick points for you. Cabozantinib is 1 of our main go-to drugs for RCC [renal cell carcinoma]. It’s been proposed to be particularly effective for bone metastases, right? There were recent data for cabo...

May 2nd, 2022 - Arnab Basu, MD: In your experience, what are some of the commonly observed adverse events in this IO [immunotherapy]/IO combination therapy regimen, and how do you manage those? Shawnta Anakwah, MD: Typically, the ones that I’ve seen have been ra...

Apr 28th, 2022 - Although the microorganisms colonizing our bodies have long been linked to human health and various disease states, an understanding of the potential impact of the microbiota on cancer has just begun to emerge in the past 20 years. Novel strategie...